Subject(s)
Immunotherapy/methods , Melanoma/drug therapy , Melanoma/mortality , Programmed Cell Death 1 Receptor/administration & dosage , Skin Neoplasms/drug therapy , Skin Neoplasms/mortality , Aged , Analysis of Variance , Biomarkers, Tumor/blood , Cohort Studies , Female , France , Humans , Lymphocyte Count , Lymphocytes/cytology , Male , Melanoma/pathology , Middle Aged , Multivariate Analysis , Neoplasm Invasiveness/pathology , Neoplasm Metastasis , Neoplasm Staging , Neutrophils/cytology , Patient Selection , Prognosis , Retrospective Studies , Risk Assessment , Skin Neoplasms/pathology , Survival Analysis , Treatment OutcomeABSTRACT
BACKGROUND: Plasma cell gingivitis is defined as gingival inflammation comprised of plasma cell infiltrates. This diagnostic criterion is non-specific and underlying mechanisms remain unknown. OBJECTIVES: We performed a multidisciplinary clinico-pathological review of cases previously identified as "gingivitis with plasma cell infiltrates", with assessment of putative contributing factors and critical appraisal of the final diagnosis. MATERIALS & METHODS: Cases previously identified as "gingivitis with plasma cell infiltrates" between 2000 and 2020 were included from archives from the GEMUB group, a French multidisciplinary network of physicians with expertise on oral mucosa. RESULTS: Among the 37 included cases, multidisciplinary clinico-pathological review allowed differential diagnosis in seven cases (oral lichen planus n=4, plasma cell granuloma n=1, plasmacytoma n=1, and mucous membrane pemphigoid n=1). The remaining cases were classified as "reactive plasma cell gingivitis" (induced by drugs, trauma/irritation or periodontal disease) (n=18) or "idiopathic plasma cell gingivitis" when no contributing factors were identified (n=12). Clinico-pathological characteristics did not differ significantly between "reactive" and "idiopathic" cases, preventing us from identifying specific features of "idiopathic" plasma cell gingivitis. CONCLUSION: "Plasma cell gingivitis" is a polymorphous, non-specific entity with various aetiologies, of which the diagnosis requires multidisciplinary anatomo-clinical correlation for exclusion of secondary causes of plasma cell infiltration. Although our study was limited by its retrospective design, most cases of "plasma cell gingivitis" appeared to be associated with an underlying cause. We propose a diagnostic algorithm to properly investigate such cases.
Subject(s)
Gingivitis , Periodontal Diseases , Humans , Plasma Cells , Retrospective Studies , Gingivitis/diagnosis , Diagnosis, DifferentialABSTRACT
A rapid, simple extraction method followed by qualitative screening using liquid chromatography-tandem mass spectrometry (LC-MS-MS) for drugs in oral fluid is presented. The decision points were selected to be at, or lower, than those recommended as Tier I compounds by the National Safety Council's Alcohol, Drugs and Impairment Division for toxicological investigation of driving under the influence of drug (DUID) cases and were also at, or lower, than those recommended by Substance Abuse and Mental Health Service Administration and the Department of Transportation for Federal workplace drug testing programs. The method included 30 drugs: delta-9-tetrahydrocannabinol, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyamphetamine, cocaine, benzoylecgonine, carisoprodol, meprobamate, zolpidem, alprazolam, clonazepam, 7-aminoclonazepam, diazepam, nordiazepam, lorazepam, oxazepam, temazepam, codeine, morphine, 6-acetylmorphine, buprenorphine, fentanyl, hydrocodone, hydromorphone, oxycodone, oxymorphone, methadone, tramadol and phencyclidine. Phencyclidine was included because it is in the Federal workplace program even though it is considered a Tier II drug for DUID cases. A liquid-liquid extraction method using isopropanol, hexane and ethyl acetate to extract drugs from the oral fluid-buffer mix collected in a Quantisal™ device, followed by LC-MS-MS screening, was developed and validated according to ANSI/ASB 2019 Standard Practices for Method Validation in Forensic Toxicology. Interference studies, limit of detection, precision at the decision point, ionization suppression/enhancement and processed sample stability were determined for each drug. The method was successfully applied to proficiency specimens and routine samples received in the laboratory.
Subject(s)
3,4-Methylenedioxyamphetamine , Buprenorphine , Carisoprodol , Cocaine , Meprobamate , Methamphetamine , N-Methyl-3,4-methylenedioxyamphetamine , Tramadol , 2-Propanol , Alprazolam , Amphetamines , Clonazepam , Codeine , Dronabinol , Fentanyl , Hexanes , Hydrocodone , Hydromorphone , Lorazepam , Methadone , Morphine Derivatives , Nordazepam , Oxazepam , Oxycodone , Oxymorphone , Pharmaceutical Preparations/analysis , Phencyclidine , Tandem Mass Spectrometry , Temazepam , ZolpidemABSTRACT
Importance: Chilblain-like lesions have been reported during the coronavirus 2019 (COVID-19) pandemic. The pathophysiology of such manifestations remains largely unknown. Objective: To perform a systematic clinical, histologic, and biologic assessment in a cohort of patients with chilblain-like lesions occurring during the COVID-19 pandemic. Design, Setting, and Participants: In this prospective case series carried out with a COVID-19 multidisciplinary consultation group at the University Hospital of Nice, France, 40 consecutive patients presenting with chilblain-like lesions were included. Main Outcomes and Measures: Patients underwent a thorough general and dermatologic examination, including skin biopsies, vascular investigations, biologic analyses, interferon-alpha (IFN-α) stimulation and detection, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) and serologic analysis. Results: Overall, 40 consecutive patients with chilblain-like lesions were included. Most patients were young, with a median (range) age of 22 (12-67) years; 19 were male and 21 were female. The clinical presentation was highly reproducible with chilblain-like lesions mostly on the toes. Bullous and necrotic evolution was observed in 11 patients. Acrocyanosis or cold toes were reported in 19 (47.5%) cases. Criteria compatible with COVID-19 cases were noted in 11 (27.5%) within 6 weeks prior to the eruption. The real-time PCR (rt-PCR) testing results were negative in all cases. Overall, SARS-CoV-2 serology results were positive in 12 patients (30%). D-dimer concentration levels were elevated in 24 (60.0%) cases. Cryoglobulinemia and parvovirus B19 serologic results were negative for all tested patients. The major histologic findings were features of lymphocytic inflammation and vascular damage with thickening of venule walls and pericyte hyperplasia. A significant increase of IFN-α production after in vitro stimulation was observed in the chilblain population compared with patients with mild-severe acute COVID-19. Conclusions and Relevance: Taken together, our results suggest that chilblain-like lesions observed during the COVID-19 pandemic represent manifestations of a viral-induced type I interferonopathy. Trial Registration: ClinicalTrials.gov Identifier: NCT04344119.
Subject(s)
COVID-19/complications , Chilblains/etiology , Adolescent , Adult , Aged , COVID-19/immunology , Chilblains/immunology , Child , Female , Humans , Interferon-alpha/immunology , Male , Middle Aged , Prospective Studies , Young AdultABSTRACT
The number of drivers using drugs has increased over the last few years, and is likely to continue its upward trend. Testing drivers for alcohol use is routine and standardized, but the same is not true for the identification of driving under the influence of drugs (DUID). The Drug Evaluation and Classification Program (DECP) was developed to train police officers to recognize the signs and symptoms of recent drug use and remains an invaluable program; however, there are insufficient numbers of these highly trained drug recognition experts (DREs) available to attend every potential drug involved traffic incident. While blood and urine samples are used to test for drugs in a driver, both have disadvantages, particularly as they pertain to the length of time required after a traffic stop to sample collection. Therefore, the development of oral fluid testing devices which can be operated at the roadside and have the potential to assist officers in the identification of drug use is a major advancement in DUID cases. This project evaluated the performance of one instrumental oral fluid roadside testing device (Alere DDS®2) compared to DRE opinion, oral fluid laboratory-based analysis, and routine blood testing. The results showed that there was a good correlation with DRE observations and the device performance was >80% in all drug categories compared to laboratory-based analytical testing, both in oral fluid and blood, with few exceptions. The instrument can be considered a useful tool to assist law enforcement in identifying a drugged driver. Because the device does not test for all potentially impairing drugs, the opinion of the police officer regarding the condition of the driver should still be considered the most important aspect for arrest and further action.
Subject(s)
Driving Under the Influence , Pharmaceutical Preparations/analysis , Saliva/chemistry , Substance Abuse Detection/methods , Adolescent , Adult , Aged , Humans , Middle Aged , Pharmaceutical Preparations/blood , Substance Abuse Detection/instrumentation , Young AdultABSTRACT
This paper describes the determination of tetrahydrocannabinol (THC) and its metabolite, 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in oral fluid using solid-phase extraction and liquid chromatography with tandem mass spectral detection (LC-MS-MS) and its application to proficiency specimens. The method employs collection of oral fluid with the Quantisal™ device, base hydrolysis, solid-phase extraction and LC-MS-MS in positive ion electrospray mode. Because the concentration of the metabolite in oral fluid is quite low, extremely sensitive analytical methods are necessary. The requisite sensitivity was achieved by a simple, rapid derivatization of the compound after extraction. The derivatization conditions did not affect parent THC. The method was fully validated using standard parameters including linearity, sensitivity, accuracy, intra-day and inter-day imprecision, drug recovery from the collection pad, limit of quantitation, limit of detection and matrix effects. The procedure was applied to oral fluid proficiency specimens previously analyzed to assess the stability of THC-COOH.
Subject(s)
Dronabinol/analogs & derivatives , Dronabinol/analysis , Saliva/chemistry , Substance Abuse Detection , Analytic Sample Preparation Methods , Biotransformation , Chromatography, High Pressure Liquid , Dronabinol/chemistry , Dronabinol/pharmacokinetics , Drug Stability , Forensic Toxicology/methods , Glucuronides/metabolism , Humans , Limit of Detection , Marijuana Smoking/metabolism , Reproducibility of Results , Solid Phase Extraction , Spectrometry, Mass, Electrospray Ionization , Tandem Mass SpectrometryABSTRACT
The determination of carisoprodol and its metabolite meprobamate in oral fluid using solid-phase extraction and liquid chromatography with tandem mass spectral detection (LC-MS-MS) and its application to authentic specimens is described. The method employs collection of oral fluid with the Quantisal device, extraction using cation exchange/hydrophobic solid-phase columns, and LC-MS-MS in positive ion electrospray mode. The method was fully validated using various parameters, including selectivity, linearity, accuracy, intra-day and inter-day imprecision, drug recovery from the collection pad, limit of quantitation and matrix effects. The method was applied to both routine research specimens and an authentic specimen taken from an individual prescribed a daily dose of 350 mg carisoprodol following surgery.
Subject(s)
Carisoprodol/analysis , Meprobamate/analysis , Muscle Relaxants, Central/analysis , Saliva/chemistry , Calibration , Carisoprodol/pharmacokinetics , Chromatography, High Pressure Liquid , Humans , Muscle Relaxants, Central/pharmacokinetics , Reproducibility of Results , Solid Phase Extraction , Spectrometry, Mass, Electrospray Ionization , Substance Abuse Detection , Tandem Mass SpectrometryABSTRACT
A retrospective analysis of data from oral fluid specimens was conducted in order to identify a relevant cutoff concentration for opiates and/or synthetic opiates in oral fluid. Previously proposed regulations from the Substance Abuse and Mental Health Services Administration (SAMHSA) have recommended 40 µg/L as a cutoff concentration. In this study, data from oral fluid specimens collected using the Quantisal™ device and screened with enzyme linked immunosorbent assays (ELISA) for both opiates and oxycodone were retrospectively assessed for screen positives > 20 µg/L and those between negative and 20 µg/L. Specimens identified at these concentrations were then analyzed using liquid chromatography with tandem mass spectral detection using a fully validated procedure. Overall, 156 positive specimens were identified using 40 µg/L; 191 specimens using 20 µg/L; and 241 specimens between negative and 20 µg/L. Specifically, the number of 6-acetylmorphine (6-AM) positives increased from 10 to 16; morphine 4 to 9; codeine from 11 to 19; oxycodone from 56 to 74; hydrocodone from 73 to 119; and hydromorphone from 2 to 4 when specimens with enzyme inhibition between negative and 20 µg/L were analyzed. For workplace testing where only codeine, morphine, and 6-AM are considered, the use of a lowered cutoff concentration produced significant increases in the positive rate.
Subject(s)
Analgesics, Opioid/analysis , Saliva/chemistry , Substance Abuse Detection , Enzyme-Linked Immunosorbent Assay , Humans , Illicit Drugs/analysis , Limit of Detection , Retrospective StudiesABSTRACT
At the end of 2010, the U.S. Drug Enforcement Administration (DEA) used its emergency scheduling authority to temporarily control five chemicals, JWH-018, JWH-073, JWH-200, CP-47497, and cannabicyclohexanol (CP-47497 C8), often referred to as "Spice", K2, or "synthetic cannabinoids" because of their reported cannabis-like effects. JWH-250 is commonly encountered, and HU-210 was already controlled, so these were also included in the research. We report the first analytical procedure for the simultaneous determination of these compounds in oral fluid specimens collected with the Quantisal™ device using solid-phase extraction and liquid chromatography with tandem mass spectrometry. The method was validated and applied to specimens taken from two individuals who had purchased the synthetic compounds while still legally available in the U.S. After a single session of smoking "Blueberry Posh", the peak concentration of JWH-018 detected was 35 µg/L 20 min after smoking; JWH-018 was still detectable 12 h after a single intake. After a single session of smoking "Black Mamba", JWH-018 was detected with a peak concentration of 5 µg/L after 20 min. In this subject, the compound was not detectable after 12 h.
Subject(s)
Cannabinoids/analysis , Chromatography, Liquid/methods , Illicit Drugs/analysis , Saliva/chemistry , Spectrometry, Mass, Electrospray Ionization/methods , Substance Abuse Detection/methods , Calibration , Drug Stability , Humans , Limit of Detection , Reference Standards , Reproducibility of Results , Specimen HandlingABSTRACT
The concentration of tetrahydrocannabinol (THC) and its main metabolite 11-nor-Δ(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) as well as cannabinol (CBN), and cannabidiol (CBD) were measured in oral fluid following realistic exposure to marijuana in a Dutch coffee-shop. Ten healthy subjects, who were not marijuana smokers, volunteered to spend 3h in two different coffee shops in Groningen, The Netherlands. Subjects gave two oral fluid specimens at each time point: before entering the store, after 20 min, 40 min, 1h, 2h, and 3h of exposure. The specimens were collected outside the shop. Volunteers left the shop completely after 3h and also provided specimens approximately 12-22 h after beginning the exposure. The oral fluid specimens were subjected to immunoassay screening; confirmation for THC, cannabinol and cannabidiol using GC/MS; and THC-COOH using two-dimensional GC-GC/MS. THC was detectable in all oral fluid specimens taken 3h after exposure to smoke from recreationally used marijuana. In 50% of the volunteers, the concentration at the 3h time-point exceeded 4 ng/mL of THC, which is the current recommended cut-off concentration for immunoassay screening; the concentration of THC in 70% of the oral fluid specimens exceeded 2 ng/mL, currently proposed as the confirmatory cut-off concentration. THC-COOH was not detected in any specimens from passively exposed individuals. Therefore it is recommended that in order to avoid false positive oral fluid results assigned to marijuana use, by analyzing for only THC, the metabolite THC-COOH should also be monitored.